A multi-stakeholder consensus has laid out a roadmap intended to make clinical trials for rare childhood CNS tumors more practical and more inclusive. The effort, published in the British Journal of Cancer, targets structural bottlenecks that often leave these diseases behind in trial innovation. The authors argue that clinical trial systems have struggled to keep pace with scientific advances in rare pediatric oncology. The roadmap is designed to improve feasibility, trial operations, and participant access by aligning stakeholders around trial design and execution needs. For sponsors and investigators, the document functions as an attempt to standardize thinking around endpoints, trial infrastructure, and the operational models required to run studies in very small patient populations. The consensus approach reflects broader recognition that rare pediatric oncology requires coordinated trial platforms and faster operational decision-making to sustain recruitment and scientific rigor.